


particularly the disclosure relating to therapeutic compositions starting on page 6 and to the methods of administering therapeutic compositions disclosed on page 7 and further supported by the exemplification on pages 8-12.

The amended claims and the new claims do not include any multiple dependent claims.

The amendments to original claims 1-5 are handmarked on the enclosed copy of these original claims.

Respectfully submitted,



HERBERT GOODMAN
Reg. No. 17,081

Frishauf, Holtz, Goodman,
Langer & Chick, P.C.
767 Third Ave., 25th floor
New York, NY 10017-2023
Telephone: (212) 319-4900
Facsimile: (212) 319-5101

HG/lpv

Enc.: Handmarked copy of original claims 1-5

Claims

1. A therapeutic agent_n ^{composition} for a corneal disorder comprising a compound having an effect of activating Rho as an active ingredient_n ^{and a pharmacological carrier}
2. The therapeutic agent_n ^{composition} for the corneal disorder as claimed in claim 1, wherein the compound having the effect of activating Rho is lysophosphatidic acid or an acyl derivative thereof.
3. The therapeutic agent_n ^{composition} for the corneal disorder as claimed in claim 2, wherein ^{said compound having the effect of activating Rho} [the acyl derivative of lysophosphatidic acid] is oleoyl lysophosphatidic acid.
4. The therapeutic agent_n ^{composition} for the corneal disorder as claimed in ^{claim 1} [any one of claims 1 to 3], wherein the corneal disorder is corneal ulcer, corneal erosion, keratitis or dry eye.
5. A corneal epithelial migration promoter_n ^{composition} comprising a compound having an effect of activating Rho as an active ingredient_n ^{and a pharmacological carrier}